FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360608082> ?p ?o ?g. }

• W4360608082 abstract "You have accessJournal of UrologyCME1 Apr 2023MP10-09 THE REAL-WORLD EFFECTIVENESS OF PREVENTIVE PHARMACOLOGICAL THERAPY John Hollingsworth, Mary Oerline, Ryan Hsi, Joseph Crivelli, Noah Krampe, John Asplin, and Vahakn Shahinian John HollingsworthJohn Hollingsworth More articles by this author , Mary OerlineMary Oerline More articles by this author , Ryan HsiRyan Hsi More articles by this author , Joseph CrivelliJoseph Crivelli More articles by this author , Noah KrampeNoah Krampe More articles by this author , John AsplinJohn Asplin More articles by this author , and Vahakn ShahinianVahakn Shahinian More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003225.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Most efficacy results supporting preventive pharmacological therapy (PPT) used to reduce kidney stone recurrence are based on composite outcomes largely driven by imaging findings. Because these findings are surrogates for things about which patients and their clinicians care, we conducted an observational study to determine whether PPT use led to fewer symptomatic kidney stone events, requiring emergency department (ED) visit, hospitalization, or surgery. METHODS: We identified a cohort of Medicare enrollees who had a 24-hour urine collection processed by a large central laboratory (2011-2016). We linked their clinical data with their pharmacy and medical claims. Among the subset with at least one biochemistry abnormality, we distinguished those who were prescribed guideline-concordant PPT (i.e., thiazides for hypercalciuria, alkali citrate therapy for hypocitraturia or low urine pH, uric acid lowering agents for hyperuricosuria) from those who were not. We differentiated between adherent and nonadherent PPT users based on the proportion of days covered method. We fit multivariate Cox models to estimate the hazard of a symptomatic stone event as a function of PPT use. RESULTS: In total, 7,230 patients met criteria, 55% of whom had hypocitraturia. Sixty-nine percent were untreated, and 31% were prescribed concordant PPT (alkali citrate therapy was used in 66%). Compared to untreated patients, those prescribed concordant therapy and adhered to their medication had a 38% lower hazard of ED visit (P<0.01) and a 46% lower hazard of hospitalization (P=0.04). Put differently, compared to untreated patients, concordant/adherent patients had lower 2-year predicted probabilities of ED visit (4.6% vs. 7.3%) and hospitalization (1.1% vs. 2.0%) (P<0.05 for each comparison). A similar pattern was noted for stone directed surgery but was not significant (Figure 1). CONCLUSIONS: Our findings help strengthen the evidence base for PPT use, providing real-world data on its clinical effectiveness. Source of Funding: National Institute of Diabetes and Digestive and Kidney Diseases R01DK121709 (to J.H.) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e117 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information John Hollingsworth More articles by this author Mary Oerline More articles by this author Ryan Hsi More articles by this author Joseph Crivelli More articles by this author Noah Krampe More articles by this author John Asplin More articles by this author Vahakn Shahinian More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4360608082 created "2023-03-24" @default.
• W4360608082 creator A5004739946 @default.
• W4360608082 creator A5006494970 @default.
• W4360608082 creator A5021459937 @default.
• W4360608082 creator A5061252104 @default.
• W4360608082 creator A5082554505 @default.
• W4360608082 creator A5084644000 @default.
• W4360608082 creator A5091010294 @default.
• W4360608082 date "2023-04-01" @default.
• W4360608082 modified "2023-09-23" @default.
• W4360608082 title "MP10-09 THE REAL-WORLD EFFECTIVENESS OF PREVENTIVE PHARMACOLOGICAL THERAPY" @default.
• W4360608082 doi "https://doi.org/10.1097/ju.0000000000003225.09" @default.
• W4360608082 hasPublicationYear "2023" @default.
• W4360608082 type Work @default.
• W4360608082 citedByCount "0" @default.
• W4360608082 crossrefType "journal-article" @default.
• W4360608082 hasAuthorship W4360608082A5004739946 @default.
• W4360608082 hasAuthorship W4360608082A5006494970 @default.
• W4360608082 hasAuthorship W4360608082A5021459937 @default.
• W4360608082 hasAuthorship W4360608082A5061252104 @default.
• W4360608082 hasAuthorship W4360608082A5082554505 @default.
• W4360608082 hasAuthorship W4360608082A5084644000 @default.
• W4360608082 hasAuthorship W4360608082A5091010294 @default.
• W4360608082 hasConcept C104863432 @default.
• W4360608082 hasConcept C126322002 @default.
• W4360608082 hasConcept C142724271 @default.
• W4360608082 hasConcept C177713679 @default.
• W4360608082 hasConcept C23131810 @default.
• W4360608082 hasConcept C2777724520 @default.
• W4360608082 hasConcept C2777993539 @default.
• W4360608082 hasConcept C2779403450 @default.
• W4360608082 hasConcept C2780026642 @default.
• W4360608082 hasConcept C2780182762 @default.
• W4360608082 hasConcept C512399662 @default.
• W4360608082 hasConcept C71924100 @default.
• W4360608082 hasConceptScore W4360608082C104863432 @default.
• W4360608082 hasConceptScore W4360608082C126322002 @default.
• W4360608082 hasConceptScore W4360608082C142724271 @default.
• W4360608082 hasConceptScore W4360608082C177713679 @default.
• W4360608082 hasConceptScore W4360608082C23131810 @default.
• W4360608082 hasConceptScore W4360608082C2777724520 @default.
• W4360608082 hasConceptScore W4360608082C2777993539 @default.
• W4360608082 hasConceptScore W4360608082C2779403450 @default.
• W4360608082 hasConceptScore W4360608082C2780026642 @default.
• W4360608082 hasConceptScore W4360608082C2780182762 @default.
• W4360608082 hasConceptScore W4360608082C512399662 @default.
• W4360608082 hasConceptScore W4360608082C71924100 @default.
• W4360608082 hasIssue "Supplement 4" @default.
• W4360608082 hasLocation W43606080821 @default.
• W4360608082 hasOpenAccess W4360608082 @default.
• W4360608082 hasPrimaryLocation W43606080821 @default.
• W4360608082 hasRelatedWork W2034873907 @default.
• W4360608082 hasRelatedWork W2047387678 @default.
• W4360608082 hasRelatedWork W2315026682 @default.
• W4360608082 hasRelatedWork W2345385639 @default.
• W4360608082 hasRelatedWork W2397418884 @default.
• W4360608082 hasRelatedWork W2408563085 @default.
• W4360608082 hasRelatedWork W2410442159 @default.
• W4360608082 hasRelatedWork W2589700523 @default.
• W4360608082 hasRelatedWork W3087339446 @default.
• W4360608082 hasRelatedWork W827254617 @default.
• W4360608082 hasVolume "209" @default.
• W4360608082 isParatext "false" @default.
• W4360608082 isRetracted "false" @default.
• W4360608082 workType "article" @default.